Which company developed CBL‑514?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CBL-514 Developer

CBL-514 was developed by Chong Kun Dang Pharmaceutical Corp., a South Korean pharmaceutical company. 1, 2, 3, 4

The compound is a novel small-molecule injectable lipolysis agent designed to induce targeted adipocyte apoptosis for subcutaneous fat reduction. Based on the clinical trial registrations and published research, CBL-514 has progressed through Phase IIa and Phase IIb clinical development for abdominal subcutaneous fat reduction, with studies conducted between 2022 and 2026 2, 3, 4.

The drug has demonstrated significant efficacy in reducing abdominal subcutaneous fat volume and thickness through multiple randomized, placebo-controlled trials, with a favorable safety profile characterized primarily by mild-to-moderate injection site reactions 2, 3, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.